Lonza Sells Belgium Peptides Biz to PolyPeptides Group
Lonza has agreed to sell its peptide business operations in Braine-l’Alleud, Belgium to the PolyPeptide Group, a Torrance, California-headquartered contract manufacturing organization.
The acquisition expands the total manufacturing capacity and service offerings of both the Braine site and Polypeptide. Lonza’s Braine facility, which houses approximately 280 employees, provides PolyPeptidet additional large-scale capacity in synthesis, purification, and isolation of peptides, Lonza had acquired the Braine peptide business in 2006 from UCB.
The acquisition will not affect ongoing activities at the Belgian facility before or after close, Lonza said. With this acquisition, the PolyPeptide Group will employ close to 800 people worldwide with GMP facilities in Torrance and San Diego, California; Strasbourg, France; Ambernath , India; Braine-D’Alleud, Belgium; and Malmo, Sweden.
The financial terms of the transaction, which is expected to close in the next weeks subject to customary closing conditions, were not disclosed.